Physician profile
William Thomas Corder
NPI 1154306850
$1,747.84
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $355 · 2020: $31.52 · 2021: $225 · 2022: $137 · 2023: $540 · 2024: $459.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $999.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $999.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $516.35 | 2019-2024 | Dupixent |
| Astrazeneca Pharmaceuticals Lp | $441.58 | 2019-2024 | Fasenra, Airsupra |
| Abbvie INC. | $204.18 | 2019-2024 | Skyrizi |
| Genentech USA, INC. | $171.17 | 2021-2024 | Xolair |
| Genzyme Corporation | $105.85 | 2023 | |
| Amgen INC. | $72.34 | 2022-2024 | Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $45.44 | 2023-2024 | Siliq |
| Pfizer INC. | $40.18 | 2024 | |
| Sun Pharmaceutical Industries INC. | $29.18 | 2023 | Ilumya |
| Galderma Laboratories, L.P. | $24.41 | 2024 | |
| Lilly USA, LLC | $24.12 | 2024 | Taltz |
| Glaxosmithkline, LLC. | $23.90 | 2023 | Trelegy Ellipta, Arexvy |
| Incyte Corporation | $19.50 | 2024 | Opzelura |
| Ucb, INC. | $15.17 | 2024 | Bimzelx |
| Sandoz INC. | $14.47 | 2023 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Corder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.